Equillium's primary product candidate is EQ001, a monoclonal antibody that targets the immune checkpoint receptor CD6, which plays a role in effector T cell activity and drives immuno-inflammatory diseases such as graft versus host disease, asthma, uveitis, colitis, lupus, and multiple sclerosis. In addition to EQ001, Equillium's pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway, and EQ101 and EQ102, cytokine inhibitors that selectively target IL-2, IL-9, IL-15, and IL-21. These products are in various stages of clinical development and are expected to treat severe autoimmune and inflammatory disorders with high unmet medical needs.